期刊文献+

B_(19)-Gly-B_(20)人胰岛素的分离纯化及性质研究 被引量:2

Research on the purification and characterization of B_( 19)-Gly-B_(20)human insulin
下载PDF
导出
摘要 目的研究胰岛素B链羧端的自由度对于胰岛素与受体相互作用的影响。方法在人胰岛素B链羧端 β转角区回折点B1 9与B2 0 之间插入一个Gly。结果B1 9 Gly B2 0 人胰岛素原的表达产物占细胞总蛋白量的 3 0 % ,B1 9 Gly B2 0 人胰岛素的受体活性是标准猪胰岛素的 12 1%。结论以较高的受体结合活性获得了高纯度的B1 9 Gly B2 0 人胰岛素。 PurposeThe aim is to study the effect of increased flexibility of C terminal of insulin B chain on its receptor binding activity. MethodsA Gly was inserted between B 19 and B 20 of turn in of insulin B chain β hope of providing more flexibility to its C termina. ResultsThe expression level of B 19 Gly B 20 human prolnsulin accounted for 30% of total bacterial proteins. B 19 Gly B 20 human insulin′s receptor binding activity was 121% as compared with standard porcine insulin.ConclusionPurified B 19 Gly B 20 human insulin was obtained by the common methods and its receptor binding activity was high.
作者 陈来同 孙宇
出处 《中国生化药物杂志》 CAS CSCD 2001年第5期234-236,共3页 Chinese Journal of Biochemical Pharmaceutics
基金 北京大学蛋白质工程及基因工程国家重点实验室资助项目
关键词 B19-Gly-B20人胰岛素 β转角 受体结合活性 B 19 Gly B 20 human insulin β turn Receptor binding activity
  • 相关文献

参考文献9

  • 1梁栋材,常文瑞,张季平,万柱礼.胰岛素分子与其受体结合的可能机制[J].中国科学(B辑),1991(7):715-723. 被引量:9
  • 2冯佑民 朱鞠红 等.胰岛素作用原理的研究[J].Acta Biochinica et Biophysica Sinica(生物化学与生物物理学报:英文版),1982,14(2):137-139.
  • 3陈来同,胡美浩.从基因工程小C肽人胰岛素原类似物(B-R2-A)制备人胰岛素[J].生物化学杂志,1995,11(1):1-5. 被引量:8
  • 4Tong J G,Biotechno1 Lett,1993年,15卷,661页
  • 5Hua Q X,Biochimistry,1992年,31卷,11940页
  • 6Qing X H,Nature,1991年,354卷,21期,238页
  • 7梁栋材,中国科学.B,1991年,7卷,731页
  • 8Mori K F,J Biolst Ardization,1984年,12卷,427页
  • 9冯佑民,生物化学与生物物理学报,1982年,14卷,2期,137页

二级参考文献2

共引文献14

同被引文献26

  • 1陈来同,胡美浩.从基因工程小C肽人胰岛素原类似物(B-R2-A)制备人胰岛素[J].生物化学杂志,1995,11(1):1-5. 被引量:8
  • 2陈来同,黄春媚,张曼,杨志茹,胡美浩.去B链羧端三肽人胰岛素的分离纯化及其性质研究[J].生物化学杂志,1996,12(2):187-190. 被引量:5
  • 3冯佑民 朱鞠红 等.胰岛系作用原理的研究[J].Acta Biochinica et Biophysica Sinica(生物化学与生物物理学报:英文版),1982,14(2):137-137.
  • 4DV Goeddel, DG Kleid, F Bolivar, et al. Expression in escherichia coli of chemically synthesized genes for human insulin[J], Proc Natl Acad Sci USA, 1979, 76:106
  • 5H Keen, A Glynne, J C Pickup, et al. Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men[J]. Lancet, 1980,2:398
  • 6Zinman B . The physiological replacement of insulin: an elusive goal[J]. New Engl J Med, 1989, 321(6):363
  • 7J Brange, U Ribel, J Hansen, et al. Monomeric insulins obtained by protein engineering and their medical implications[J]. Nature,1988,333:679
  • 8J Brange, D R Owens, S Kang, et al. Monomeric insulins and their experimental and clinical implications[J]. Diabetes Care, 1990, 13:923
  • 9Aa VO lund, J Brange, I Jensen, et al. In vitro and in vivo potency of insulin analogues designed for clinical use [J]. Diabetic Med,1991,8:839
  • 10Kang S, Brange J, Burch A, et al. Absorption kinetics and action profileds of subcutaneously administered insulin analogues(AspB9GluB27, AspB 10, AspB28) in healthy subje cts[J]. Diabetes Care, 1991,14:1 057

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部